Matches in SemOpenAlex for { <https://semopenalex.org/work/W2389121323> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2389121323 abstract "Objective To compare the curative effect and adverse reaction of argatroban and rivaroxaban in acute venous thrombosis patients. Methods Patients (254 cases) with venous thromboembolism in Wuhan Union Hospital from June 2010 to June 2012 were analyzed by retrospective study method. The patients were randomly divided into the control (98 cases), argatroban (101 cases), and rivaroxaban (55 cases) groups. The patients in the control group were administered with ordinary heparin 1.25×10 4 U in 48 mL normal saline, 2 mL/h, by iv continuous pumping, for 7 d. The patients in the argatroban group were administered with argatroban (40 mg/d) in 96 mL normal saline with 4 mL/h in first 2 d and 20 mg/d in 48 mL normal saline with 2 mL/h in last 5 d, the course of treatment was 7 d. The patients in the rivaroxaban group were po with rivaroxaban (10 mg/d), for 7 d as one course. The diameters of double lower limbs were measured daily, and the blood coagulation function, blood routine test , routine urine test, and occult stool test were monitored. Besides, the D-dimer level was detected before anticoagulation treatment and after 7 d of the treatment, and the bleeding tendency of patients was observed. After 7 d, all patients were po Huafalin for three or six months. INR value was tested, and the dosage of Huafalin was adjusted to maintain the INR value from 2 to 3. Results After 7 d of the treatment, the lower limb swelling remission rate of the argatroban group was 95%, and those of rivaroxaban and control groups were 89% and 96%, respectively. There was no significant difference in the three groups. The concentration of D-dimer in the three groups were no statistical difference. Adverse reactions of bleeding in argatroban and rivaroxaban groups were lower than that in the control group (P 0.05). Conclusion Argatroban and rivaroxaban as new anticoagulant drugs show no distinguishable clinical curative effect compared with the traditional ordinary heparin. Argatroban is with less adverse reaction compared to the ordinary heparin, and doesn’t cause thrombocytopenia." @default.
- W2389121323 created "2016-06-24" @default.
- W2389121323 creator A5088486710 @default.
- W2389121323 date "2013-01-01" @default.
- W2389121323 modified "2023-09-23" @default.
- W2389121323 title "Comparison of clinical efficacy between argatroban and rivaroxaban in treatment of acute venous thromboembolism" @default.
- W2389121323 hasPublicationYear "2013" @default.
- W2389121323 type Work @default.
- W2389121323 sameAs 2389121323 @default.
- W2389121323 citedByCount "0" @default.
- W2389121323 crossrefType "journal-article" @default.
- W2389121323 hasAuthorship W2389121323A5088486710 @default.
- W2389121323 hasConcept C126322002 @default.
- W2389121323 hasConcept C141071460 @default.
- W2389121323 hasConcept C197934379 @default.
- W2389121323 hasConcept C2776301958 @default.
- W2389121323 hasConcept C2776884760 @default.
- W2389121323 hasConcept C2777292125 @default.
- W2389121323 hasConcept C2777397205 @default.
- W2389121323 hasConcept C2778661090 @default.
- W2389121323 hasConcept C2779161974 @default.
- W2389121323 hasConcept C2779612170 @default.
- W2389121323 hasConcept C2780011451 @default.
- W2389121323 hasConcept C2780868729 @default.
- W2389121323 hasConcept C42219234 @default.
- W2389121323 hasConcept C71924100 @default.
- W2389121323 hasConcept C89560881 @default.
- W2389121323 hasConceptScore W2389121323C126322002 @default.
- W2389121323 hasConceptScore W2389121323C141071460 @default.
- W2389121323 hasConceptScore W2389121323C197934379 @default.
- W2389121323 hasConceptScore W2389121323C2776301958 @default.
- W2389121323 hasConceptScore W2389121323C2776884760 @default.
- W2389121323 hasConceptScore W2389121323C2777292125 @default.
- W2389121323 hasConceptScore W2389121323C2777397205 @default.
- W2389121323 hasConceptScore W2389121323C2778661090 @default.
- W2389121323 hasConceptScore W2389121323C2779161974 @default.
- W2389121323 hasConceptScore W2389121323C2779612170 @default.
- W2389121323 hasConceptScore W2389121323C2780011451 @default.
- W2389121323 hasConceptScore W2389121323C2780868729 @default.
- W2389121323 hasConceptScore W2389121323C42219234 @default.
- W2389121323 hasConceptScore W2389121323C71924100 @default.
- W2389121323 hasConceptScore W2389121323C89560881 @default.
- W2389121323 hasOpenAccess W2389121323 @default.
- W2389121323 hasRelatedWork W1561138119 @default.
- W2389121323 hasRelatedWork W192624987 @default.
- W2389121323 hasRelatedWork W1975170689 @default.
- W2389121323 hasRelatedWork W2082826915 @default.
- W2389121323 hasRelatedWork W2083284527 @default.
- W2389121323 hasRelatedWork W2128379891 @default.
- W2389121323 hasRelatedWork W2360148841 @default.
- W2389121323 hasRelatedWork W2464637540 @default.
- W2389121323 hasRelatedWork W2596251721 @default.
- W2389121323 hasRelatedWork W2790129370 @default.
- W2389121323 hasRelatedWork W2796425032 @default.
- W2389121323 hasRelatedWork W2884113475 @default.
- W2389121323 hasRelatedWork W2967568153 @default.
- W2389121323 hasRelatedWork W3028878741 @default.
- W2389121323 hasRelatedWork W3029269497 @default.
- W2389121323 hasRelatedWork W3029422471 @default.
- W2389121323 hasRelatedWork W3029856526 @default.
- W2389121323 hasRelatedWork W3032123411 @default.
- W2389121323 hasRelatedWork W3032246965 @default.
- W2389121323 hasRelatedWork W3147138657 @default.
- W2389121323 isParatext "false" @default.
- W2389121323 isRetracted "false" @default.
- W2389121323 magId "2389121323" @default.
- W2389121323 workType "article" @default.